To overcome these limitations, larger studies and further research with a prospective design and involving larger populations from various centers need to be conducted to confirm the role of PD-1 and PD-L1 as prognostic biomarkers that can be applied in clinical practice as a tool to guide optimal therapeutic options for colorectal cancer patients. This evidence concerns the gene CD274 and colorectal cancer.